Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals has reported positive results from its Phase 3 EXPAND study of maralixibat for the treatment of cholestatic pruritus in patients with biliary atresia.

The company plans to submit a New Drug Application to the FDA in the first half of 2022.